This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Denver Physician Breaks New Ground In Cochlear Implants

DENVER, Nov. 30, 2012 /PRNewswire/ -- A Swedish Medical Center ( www.SwedishHospital.com) physician is breaking new ground in the area of cochlear implants with his recent surgery on a 9-year-old girl who received the medical implant for single-sided deafness. Daniel Zeitler, M.D., a neurotologist and skull-based surgeon, is one of only a few medical professionals in the U.S. to perform the procedure for this population and diagnosis.

(Logo:  http://photos.prnewswire.com/prnh/20121130/PH21545LOGO-a )

(Photo:  http://photos.prnewswire.com/prnh/20121130/PH21545-b )

According to Zeitler, the young patient's deafness was beginning to take its toll on her both academically and socially.

"Although Claire is an excellent student, she had to sit strategically in the classroom to be able to hear. She often felt socially isolated during basketball practice or active family outings. Basically, all the things that a 9-year-old girl likes to do were slowly taken away because of her deafness," Zeitler says.

Young Claire received the cochlear implant on November 26. The MED-EL device will be activated on Dec. 18; however, Zeitler says early testing during surgery indicated it was working properly. The use of cochlear implants for single-sided deafness, and for patients as young as Claire, is an emerging practice in Europe, but is extremely rare in the U.S. In fact, the FDA has not yet approved the device for single-sided deafness, says Zeitler.

So why did Dr. Zeitler agree to this rare procedure? Because he feels Claire can benefit greatly from this technology, and he's confident the cochlear implant will dramatically improve the quality of life for this youngster sooner rather than later.

"There's a huge push to initiate clinical trials for its use in these circumstances in the U.S., but only a few anecdotal reports and small objective studies currently exist. Unfortunately, there is no good data or large-scale subjective experiences to make it the norm yet," Zeitler says.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,096.90 -106.47 -0.58%
S&P 500 2,098.53 -9.25 -0.44%
NASDAQ 4,967.1410 -12.76 -0.26%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs